Phenotypes Associated with This Genotype

Genotype
MGI:2675163

• Allelic Composition: Cd69^tm1Naka/Cd69^tm1Naka
• Genetic Background: C.129P2-Cd69^tm1Naka

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

impaired neutrophil chemotaxis ( J:84940 )

• RT-PCR analysis revealed significantly decreased CXCL1 expression levels in mutant hind paws at 4 days after treatment with anti-type II collagen antibodies and LPS, suggesting that neutrophil migration in mutant arthritic joints is reduced

• on day 10 after treatment, MCP-1 and MCP-2 expression levels in mutant mice are significantly lower than those of wild-type mice

impaired neutrophil recruitment ( J:84940 )

• at 10 days after anti-type II collagen antibody injection, neutrophil infiltration in mutant arthritic joints is reduced relative to that in similarly-treated wild-type joints

decreased susceptibility to induced arthritis ( J:84940 )

• homozygotes exhibit a less severe arthritic response to anti-type II collagen antibodies relative to similarly-treated wild-type mice

• unlike in wild-type mice, no rigidity or massive swelling is observed in mutant joints at 10 days after treatment with anti-type II collagen antibodies and LPS

• at 10 days after anti-type II collagen antibody injection, neutrophil infiltration is dramatically reduced in mutant joints relative to that in similarly-treated wild-type joints

• RT-PCR analysis revealed that mRNA levels of IL-1beta, IL-6 and MCP-1 are significantly reduced in mutant arthritic joints at 4 and 10 days after antibody injection relative to those in similarly-treated wild-type mice

• cell transfer of wild-type neutrophils, but not T cells or spleen cells, can restore the anti-type II collagen-mediated arthritic response in mutant mice to almost normal levels

skeleton

decreased susceptibility to induced arthritis ( J:84940 )

• homozygotes exhibit a less severe arthritic response to anti-type II collagen antibodies relative to similarly-treated wild-type mice

• unlike in wild-type mice, no rigidity or massive swelling is observed in mutant joints at 10 days after treatment with anti-type II collagen antibodies and LPS

• at 10 days after anti-type II collagen antibody injection, neutrophil infiltration is dramatically reduced in mutant joints relative to that in similarly-treated wild-type joints

• RT-PCR analysis revealed that mRNA levels of IL-1beta, IL-6 and MCP-1 are significantly reduced in mutant arthritic joints at 4 and 10 days after antibody injection relative to those in similarly-treated wild-type mice

• cell transfer of wild-type neutrophils, but not T cells or spleen cells, can restore the anti-type II collagen-mediated arthritic response in mutant mice to almost normal levels

cellular

impaired neutrophil chemotaxis ( J:84940 )

• RT-PCR analysis revealed significantly decreased CXCL1 expression levels in mutant hind paws at 4 days after treatment with anti-type II collagen antibodies and LPS, suggesting that neutrophil migration in mutant arthritic joints is reduced

• on day 10 after treatment, MCP-1 and MCP-2 expression levels in mutant mice are significantly lower than those of wild-type mice

hematopoietic system

impaired neutrophil chemotaxis ( J:84940 )

• RT-PCR analysis revealed significantly decreased CXCL1 expression levels in mutant hind paws at 4 days after treatment with anti-type II collagen antibodies and LPS, suggesting that neutrophil migration in mutant arthritic joints is reduced

• on day 10 after treatment, MCP-1 and MCP-2 expression levels in mutant mice are significantly lower than those of wild-type mice

impaired neutrophil recruitment ( J:84940 )

• at 10 days after anti-type II collagen antibody injection, neutrophil infiltration in mutant arthritic joints is reduced relative to that in similarly-treated wild-type joints